Monoclonal Antibody Therapeutics
•152 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (152)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Lilly relies on monoclonal antibody therapeutics across indications.
|
$985.74B |
$1063.02
+2.07%
|
|
JNJ
Johnson & Johnson
Johnson & Johnson's portfolio includes multiple monoclonal antibody therapeutics (e.g., DARZALEX, CARVYKTI, TECVAYLI, TALVEY) across oncology and immunology.
|
$492.05B |
$205.33
+0.50%
|
|
ABBV
AbbVie Inc.
AbbVie directly commercializes monoclonal antibody therapeutics (e.g., Skyrizi) as a core immunology asset.
|
$388.96B |
$223.91
+1.69%
|
|
AZN
AstraZeneca PLC
AZN develops monoclonal antibody therapeutics across oncology and immunology.
|
$282.78B |
$94.78
+3.90%
|
|
MRK
Merck & Co., Inc.
Keytruda and other antibody therapies place Merck in monoclonal antibody therapeutics.
|
$268.36B |
$109.05
+1.49%
|
|
AMGN
Amgen Inc.
Amgen's portfolio includes monoclonal antibody therapeutics such as Repatha and tezepelumab (TEZSPIRE).
|
$172.66B |
$329.68
+2.79%
|
|
GILD
Gilead Sciences, Inc.
Trodelvy’s antibody component and other cancer therapies align with Monoclonal Antibody Therapeutics.
|
$146.79B |
$121.58
+2.77%
|
|
PFE
Pfizer Inc.
Monoclonal antibody therapeutics represent a major therapeutic modality in Pfizer's portfolio and oncology pipeline.
|
$143.11B |
$25.51
+1.35%
|
|
BMY
Bristol-Myers Squibb Company
Opdivo is a monoclonal antibody immuno-oncology therapy, a core direct product in BMY's Growth Portfolio.
|
$108.00B |
$54.65
+2.99%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Regeneron’s core business centers on monoclonal antibody therapeutics (e.g., Dupixent, Libtayo).
|
$80.89B |
$772.67
+1.24%
|
|
ZTS
Zoetis Inc.
Zoetis employs monoclonal antibodies for OA pain and dermatology therapies (e.g., Librela, Solensia, Cytopoint), defining a core Monoclonal Antibody Therapeutics product line.
|
$57.33B |
$129.53
+0.12%
|
|
TAK
Takeda Pharmaceutical Company Limited
Entrvyo/vedolizumab and other monoclonal antibody therapies place Takeda in Monoclonal Antibody Therapeutics.
|
$49.74B |
$15.80
+0.73%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$47.89B |
$801.07
+0.02%
|
|
ONC
BeOne Medicines Ltd.
TEVIMBRA is a monoclonal antibody therapy, placing the company in monoclonal antibody therapeutics.
|
$35.28B |
$321.73
+0.45%
|
|
BIIB
Biogen Inc.
Biogen's portfolio includes monoclonal antibody therapeutics (e.g., LEQEMBI) as a core modality.
|
$25.60B |
$182.07
+4.26%
|
|
BNTX
BioNTech SE
The company develops monoclonal antibody therapeutics (including bispecifics) for cancer, a core product area.
|
$23.22B |
$98.44
+1.64%
|
|
GMAB
Genmab A/S
Genmab develops and commercializes monoclonal antibody therapeutics (e.g., antibody-based oncology medicines).
|
$21.04B |
$33.10
+4.10%
|
|
INCY
Incyte Corporation
Monoclonal Antibody Therapeutics is a direct product modality for Monjuvi (tafasitamab) and similar antibody-based cancer therapies.
|
$19.88B |
$107.14
+5.26%
|
|
ROIV
Roivant Sciences Ltd.
Immunovant's FcRn-targeting therapies (e.g., IMVT-1402, batoclimab) are monoclonal antibody therapeutics.
|
$14.55B |
$21.46
+0.77%
|
|
SMMT
Summit Therapeutics Inc.
Ivonescimab is an antibody-based therapeutic, aligning with Monoclonal Antibody Therapeutics as a core modality.
|
$12.96B |
$18.90
+8.37%
|
|
RDY
Dr. Reddy's Laboratories Limited
Monoclonal antibody therapeutics emphasis via biosimilar strategies (e.g., abatacept, rituximab, pembrolizumab collaboration).
|
$11.53B |
$13.87
+0.36%
|
|
ELAN
Elanco Animal Health Incorporated
Monoclonal Antibody Therapeutics platform (CPMA and IL‑31 related programs) constitutes a key technology and product approach.
|
$11.45B |
$23.62
+2.49%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a monoclonal antibody therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$10.58B |
$166.29
-4.64%
|
|
RNA
Avidity Biosciences, Inc.
Monoclonal Antibody Therapeutics: uses antibody component for targeting in the AOC platform.
|
$9.27B |
$72.20
+0.18%
|
|
MRUS
Merus N.V.
Core product category: monoclonal antibody therapeutics used in cancer indications.
|
$6.81B |
$90.00
|
|
TGTX
TG Therapeutics, Inc.
BRIUMVI is TG Therapeutics' flagship monoclonal antibody therapeutic (anti-CD20) for relapsing MS, the core product driving revenue and growth.
|
$4.74B |
$29.21
-2.29%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.62B |
$77.63
+0.15%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.35B |
$25.53
+2.24%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.11B |
$41.23
-3.58%
|
|
CNTA
Centessa Pharmaceuticals plc
LockBody is an antibody-based platform; its advances map to 'Monoclonal Antibody Therapeutics'.
|
$3.09B |
$22.89
-0.56%
|
|
KNSA
Kiniksa Pharmaceuticals, Ltd.
KPL-387 is a monoclonal antibody targeting IL-1R1, placing the pipeline in monoclonal antibody therapeutics.
|
$3.04B |
$42.84
+4.34%
|
|
VERA
Vera Therapeutics, Inc.
Atacicept is a biologic therapeutic (dual BAFF/APRIL inhibitor) with a monoclonal antibody–like profile, placing Vera's lead program under Monoclonal Antibody Therapeutics.
|
$3.00B |
$46.07
-2.12%
|
|
BEAM
Beam Therapeutics Inc.
BEAM-103 involves an anti-CD117 monoclonal antibody; includes Monoclonal Antibody Therapeutics as part of its conditioning strategy.
|
$2.72B |
$28.43
+5.92%
|
|
VRDN
Viridian Therapeutics, Inc.
Lead programs Veligrotug and VRDN-003 are monoclonal antibodies targeting IGF-1R, i.e., Monoclonal Antibody Therapeutics.
|
$2.47B |
$30.47
+0.89%
|
|
ADPT
Adaptive Biotechnologies Corporation
Monoclonal Antibody Therapeutics tag aligns with autoreactive TCR targeting and antibody programs.
|
$2.46B |
$15.86
-1.95%
|
|
RCUS
Arcus Biosciences, Inc.
Domvanalimab is a monoclonal antibody therapeutic, placing Arcus in the Monoclonal Antibody Therapeutics category.
|
$2.32B |
$21.55
-1.03%
|
|
RARE
Ultragenyx Pharmaceutical Inc.
UX143 is a monoclonal antibody; Ultragenyx' portfolio includes monoclonal antibody therapeutics (Crysvita, Evkeeza, UX143).
|
$2.23B |
$22.52
-2.55%
|
|
ZLAB
Zai Lab Limited
Significant monoclonal antibody therapeutics activity across oncology/immunology assets.
|
$1.99B |
$18.27
+1.00%
|
|
OGN
Organon & Co.
Monoclonal antibody therapeutics including Emgality marketed within Organon's portfolio.
|
$1.93B |
$8.07
+8.47%
|
|
ZYME
Zymeworks Inc.
Company develops monoclonal antibody therapeutics as a core modality.
|
$1.92B |
$23.81
-6.55%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$1.81B |
$29.75
-0.70%
|
|
SNDX
Syndax Pharmaceuticals, Inc.
Niktimvo axatilimab-csfr is a monoclonal antibody therapy, fitting Monoclonal Antibody Therapeutics.
|
$1.74B |
$20.38
+0.77%
|
|
IMNM
Immunome, Inc.
Antibody-based therapeutics component of ADCs justifies Monoclonal Antibody Therapeutics tagging.
|
$1.72B |
$19.39
-1.60%
|
|
CLDX
Celldex Therapeutics, Inc.
Barzolvolimab is a therapeutic monoclonal antibody, placing Celldex in Monoclonal Antibody Therapeutics.
|
$1.70B |
$26.18
+2.27%
|
|
UPB
Upstream Bio, Inc.
Verekitug is a monoclonal antibody therapeutic targeting the TSLP receptor, directly aligning with Monoclonal Antibody Therapeutics.
|
$1.41B |
$25.52
-2.32%
|
|
NRIX
Nurix Therapeutics, Inc.
The narrative references antibody therapies in addition to small molecule degraders, aligning with Monoclonal Antibody Therapeutics.
|
$1.34B |
$17.12
-2.12%
|
|
KOD
Kodiak Sciences Inc.
Lead assets are monoclonal antibody therapeutics designed for retinal disease, aligning with Monoclonal Antibody Therapeutics.
|
$1.32B |
$25.04
+0.16%
|
|
TRML
Tourmaline Bio, Inc.
Pacibekitug is a monoclonal antibody therapeutic targeting IL-6, fitting Monoclonal Antibody Therapeutics.
|
$1.23B |
$47.98
+0.01%
|
|
ANAB
AnaptysBio, Inc.
Lead programs are monoclonal antibody therapeutics (antibodies such as rosnilimab, ANB033, ANB101).
|
$1.21B |
$43.80
+1.39%
|
|
DNTH
Dianthus Therapeutics, Inc.
Lead product is a monoclonal antibody therapeutic targeting active C1s, a core product category.
|
$1.19B |
$36.28
-1.65%
|
|
INBX
Inhibrx Biosciences, Inc.
Monoclonal antibody therapeutics addressing cancer targets with multivalent formats.
|
$1.11B |
$78.03
+1.49%
|
|
BHVN
Biohaven Ltd.
BHVN's Trop2 ADC program aligns with Monoclonal Antibody Therapeutics as a core oncology modality.
|
$1.05B |
$9.65
-2.77%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$1.05B |
$13.78
-10.55%
|
|
ABCL
AbCellera Biologics Inc.
Company is developing monoclonal antibody therapeutics through wholly-owned programs ABCL635 and ABCL575.
|
$1.02B |
$3.88
+13.27%
|
|
ERAS
Erasca, Inc.
ERAS-12 is an EGFR biparatopic antibody, constituting Monoclonal Antibody Therapeutics.
|
$1.02B |
$3.58
+6.07%
|
|
XNCR
Xencor, Inc.
Core output includes engineered monoclonal antibody therapeutics via the XmAb platform.
|
$1.02B |
$13.83
-3.08%
|
|
OPK
OPKO Health, Inc.
ModeX antibody therapies fall under monoclonal antibody therapeutics.
|
$1.02B |
$1.31
+2.73%
|
|
BCAX
Bicara Therapeutics Inc. Common Stock
Lead product is a monoclonal antibody–type therapeutic, aligning with Monoclonal Antibody Therapeutics.
|
$879.01M |
$15.96
-0.93%
|
|
ALMS
Alumis Inc. Common Stock
Lonigutamab is a monoclonal antibody therapy, a direct product in the biopharma pipeline.
|
$864.77M |
$16.39
+97.17%
|
|
NKTR
Nektar Therapeutics
NKTR-0165 is a monoclonal antibody therapeutic (TNFR2 agonist), aligning with Monoclonal Antibody Therapeutics.
|
$845.76M |
$43.16
-2.95%
|
|
OCS
Oculis Holding AG
OCS-02 Licaminlimab is an antibody-based therapeutic (monoclonal antibody therapeutics).
|
$828.41M |
$20.67
+4.66%
|
|
JANX
Janux Therapeutics, Inc.
Therapies revolve around monoclonal antibody-based modalities (including bispecific antibodies).
|
$826.29M |
$13.27
-3.49%
|
|
VIR
Vir Biotechnology, Inc.
VIR's antibody-based approaches include monoclonal antibody therapeutics targeting cancer antigens.
|
$804.33M |
$5.97
+3.20%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
ADC programs involve monoclonal antibody components; ARR-217 implies monoclonal antibody therapeutics as part of the ADC strategy.
|
$792.31M |
$18.46
-5.45%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$723.50M |
$12.90
+0.66%
|
|
ZBIO
Zenas BioPharma, Inc.
Obexelimab is a monoclonal antibody therapeutic developed by the company.
|
$699.45M |
$15.02
-9.60%
|
|
EBS
Emergent BioSolutions Inc.
Ebanga is a monoclonal antibody therapeutic developed by Emergent for Ebola; this aligns with the Monoclonal Antibody Therapeutics investable theme.
|
$685.56M |
$13.05
+1.56%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY therapeutics are monoclonal antibody–based biologics, aligning with Monoclonal Antibody Therapeutics.
|
$679.44M |
$4.10
-0.49%
|
|
CGEM
Cullinan Therapeutics, Inc.
Antibody-based therapeutics (monoclonal antibodies) are a direct product modality for CLN-978 and velinotamig.
|
$590.15M |
$10.13
+1.45%
|
|
ABSI
Absci Corporation
Internal programs ABS-101/ABS-201/ABS-301/ABS-501 are antibody-based therapeutics targeting oncology and immunology, aligning with Monoclonal Antibody Therapeutics.
|
$559.21M |
$3.87
+3.34%
|
|
IMAB
I-Mab
I-Mab develops monoclonal antibody therapeutics, including uliledlimab (CD73 antibody) and other antibody-based assets.
|
$533.68M |
$4.64
|
|
ANNX
Annexon, Inc.
Annexon's lead programs are monoclonal antibody therapeutics (ANX005, ANX009) targeting C1q.
|
$515.37M |
$4.67
-6.87%
|
|
RAPT
RAPT Therapeutics, Inc.
RPT904 is a monoclonal antibody therapeutic, fitting Monoclonal Antibody Therapeutics.
|
$493.16M |
$30.80
+3.29%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$489.85M |
$8.92
-1.98%
|
|
VNDA
Vanda Pharmaceuticals Inc.
Imsidolimab is a monoclonal antibody therapeutic targeting IL-36R for generalized pustular psoriasis.
|
$465.03M |
$8.08
+2.67%
|
|
SIGA
SIGA Technologies, Inc.
SIGA's pipeline includes fully human monoclonal antibodies licensed from Vanderbilt, aligning with Monoclonal Antibody Therapeutics.
|
$457.56M |
$6.66
+4.15%
|
|
PRTC
PureTech Health plc
LYT-200 is a monoclonal antibody therapeutic, a core biologics modality.
|
$429.19M |
N/A
|
|
IMMP
Immutep Limited
IMP761 is described as a LAG-3 agonist antibody, aligning with Monoclonal Antibody Therapeutics.
|
$422.12M |
$2.92
+0.86%
|
|
ADCT
ADC Therapeutics S.A.
ZYNLONTA uses a monoclonal antibody as its targeting moiety, fitting Monoclonal Antibody Therapeutics.
|
$400.50M |
$3.52
-0.98%
|
|
YMAB
Y-mAbs Therapeutics, Inc.
DANYELZA (naxitamab-gqgk) is a monoclonal antibody therapeutic.
|
$389.89M |
$8.61
|
|
ITOS
iTeos Therapeutics, Inc.
Belrestotug is a monoclonal antibody targeting TIGIT, indicating direct production of monoclonal antibody therapeutics.
|
$388.48M |
$10.15
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 is a humanized monoclonal antibody targeting uPAR, fitting Monoclonal Antibody Therapeutics.
|
$380.87M |
$56.59
-8.33%
|
|
VIGL
Vigil Neuroscience, Inc.
Direct product: Vigil's lead program iluzanebart is a fully human monoclonal antibody TREM2 agonist, categorizing under Monoclonal Antibody Therapeutics.
|
$375.71M |
$8.05
|
|
ACIU
AC Immune S.A.
Monoclonal Antibody Therapeutics – AC Immune develops conformation-specific monoclonal antibodies via SupraAntigen platforms.
|
$351.44M |
$3.48
-1.28%
|
|
ACRS
Aclaris Therapeutics, Inc.
Bosakitug and other assets are monoclonal antibody therapeutics, matching Monoclonal Antibody Therapeutics.
|
$287.08M |
$2.63
-0.57%
|
|
IVVD
Invivyd, Inc.
Invivyd's PEMGARDA and pipeline candidate VYD2311 are monoclonal antibody therapeutics targeting evolving viral threats, making Monoclonal Antibody Therapeutics the core product category.
|
$285.94M |
$2.29
-3.99%
|
|
FBRX
Forte Biosciences, Inc.
FB102 is a monoclonal antibody therapeutic targeting CD122, directly matching Monoclonal Antibody Therapeutics.
|
$280.49M |
$23.79
+5.43%
|
|
ZURA
Zura Bio Limited
Crebankitug and torudokimab are monoclonal antibodies in Zura Bio's pipeline (Monoclonal Antibody Therapeutics).
|
$261.37M |
$4.01
-0.25%
|
|
SLRN
Acelyrin, Inc.
Lonigutamab is a monoclonal antibody therapeutic (IGF-1R) being developed as a treatment for TED, aligning with Monoclonal Antibody Therapeutics.
|
$228.61M |
$2.27
|
|
VYGR
Voyager Therapeutics, Inc.
VY7523 is a monoclonal antibody targeting tau, category: Monoclonal Antibody Therapeutics.
|
$226.31M |
$4.00
-1.96%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$210.83M |
$16.09
+0.37%
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$186.34M |
$3.97
+2.06%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$178.44M |
$1.93
-2.04%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$177.73M |
$0.27
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$167.37M |
$1.38
-4.51%
|
|
SRZN
Surrozen, Inc.
Company develops monoclonal antibody therapeutics targeting tissue-specific Wnt signaling.
|
$163.69M |
$19.75
+3.40%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$161.94M |
$1.67
+4.37%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$157.72M |
$1.46
-4.58%
|
|
THTX
Theratechnologies Inc.
Trogarzo is a monoclonal antibody therapy for multidrug-resistant HIV, a direct product offering.
|
$155.87M |
$3.39
|
|
CBIO
Crescent Biopharma, Inc.
The therapies are monoclonal antibody–based biologics, including antibody modalities.
|
$154.35M |
$11.29
+1.62%
|
Showing page 1 of 2 (152 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
